Australia markets closed

Almirall SA (E2Z.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
8.07+0.28 (+3.66%)
As of 08:05AM CEST. Market open.
Full screen
Previous close7.78
Open8.07
Bid8.06 x 1000000
Ask8.27 x 1000000
Day's range8.07 - 8.07
52-week range7.11 - 9.97
Volume0
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Investing.com

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).